Idrabiotaparinux sodium + Idraparinux sodium + Avidin + Placebo (for Avidin)
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Deep Venous Thrombosis
Conditions
Deep Venous Thrombosis
Trial Timeline
Apr 1, 2006 → Jan 1, 2008
NCT ID
NCT00311090About Idrabiotaparinux sodium + Idraparinux sodium + Avidin + Placebo (for Avidin)
Idrabiotaparinux sodium + Idraparinux sodium + Avidin + Placebo (for Avidin) is a phase 3 stage product being developed by Sanofi for Deep Venous Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00311090. Target conditions include Deep Venous Thrombosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00311090 | Phase 3 | Completed |
Competing Products
20 competing products in Deep Venous Thrombosis